SHC1 and breast neoplasm: Given the pleotropic mechanism of action of ShcA in potentiating breast cancer progression, ShcA-targeted therapies would further elicit additional tumoricidal responses including, but not limited to, impaired angiogenesis in breast tumours to increase the likelihood of therapeutic success18, 19.